Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE: 002399)

Shenzhen Hepalink Pharmaceutical Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	2,333	1,852	2,139	2,944	2,712	1,278
Short-Term Investments	-	-	-	-	74.21	-
Trading Asset Securities	333.42	414.18	1,312	981.16	828.21	112.64
Cash & Short-Term Investments	2,667	2,266	3,450	3,925	3,615	1,390
Cash Growth	5.61%	-34.33%	-12.10%	8.59%	159.98%	-30.28%
Accounts Receivable	1,325	1,275	1,626	1,543	1,694	1,316
Other Receivables	348.85	120.43	134.82	243.81	184.16	389.02
Receivables	1,674	1,395	1,761	1,787	1,878	1,705
Inventory	6,022	6,654	6,844	4,708	3,168	2,374
Other Current Assets	344.38	289.01	334.53	349.43	467.34	525.4
Total Current Assets	10,707	10,604	12,390	10,770	9,129	5,996
Property, Plant & Equipment	2,637	2,634	2,477	2,537	2,571	2,576
Long-Term Investments	1,932	2,514	2,464	2,618	3,999	3,280
Goodwill	2,337	2,322	2,351	2,152	2,203	2,355
Other Intangible Assets	448.79	474.57	522.87	546.87	615.95	671.9
Long-Term Deferred Tax Assets	259.42	320.5	141.48	121.72	83.94	117.75
Long-Term Deferred Charges	210.16	211.07	244.71	241.88	230.33	132.06
Other Long-Term Assets	41.86	122.79	224.95	120.85	194.36	114.89
Total Assets	18,574	19,203	20,816	19,108	19,026	15,242
Accounts Payable	378.17	302.22	427.43	385.79	239.22	228.66
Accrued Expenses	307.13	371.92	377.51	398.43	395.33	355.24
Short-Term Debt	1,628	1,881	2,385	1,886	1,860	2,927
Current Portion of Long-Term Debt	1,365	1,744	1,635	1,382	622.21	1,014
Current Portion of Leases	33.43	37.8	35.69	31.75	25.6	-
Current Income Taxes Payable	186.13	157.18	112.3	113.2	43.74	63.42
Current Unearned Revenue	367.64	366.17	433.88	383.79	265.04	203.36
Other Current Liabilities	214.63	126.32	168.2	210.34	161.93	174.56
Total Current Liabilities	4,480	4,986	5,576	4,791	3,613	4,967
Long-Term Debt	1,497	1,810	2,297	2,250	3,086	2,355
Long-Term Leases	73.65	90.42	110.75	104	51.64	-
Long-Term Unearned Revenue	28.25	30.43	32.55	16.67	18.74	20.82
Long-Term Deferred Tax Liabilities	242.46	252.57	328.92	275.36	427.67	302
Other Long-Term Liabilities	16.61	14.31	29.39	26.44	24.76	17.48
Total Liabilities	6,364	7,215	8,407	7,585	7,337	7,771
Common Stock	1,467	1,467	1,467	1,467	1,467	1,247
Additional Paid-In Capital	5,869	6,356	5,859	5,944	6,035	2,634
Retained Earnings	4,595	3,931	4,861	4,184	4,212	3,411
Comprensive Income & Other	203.93	158.46	125.52	-183.36	-145.09	55.12
Total Common Equity	12,135	11,913	12,313	11,411	11,569	7,347
Minority Interest	74.4	75.23	96.72	111.96	119.6	124.1
Shareholders' Equity	12,209	11,988	12,409	11,523	11,689	7,471
Total Liabilities & Equity	18,574	19,203	20,816	19,108	19,026	15,242
Total Debt	4,596	5,563	6,464	5,654	5,645	6,297
Net Cash (Debt)	-1,930	-3,297	-3,013	-1,729	-2,030	-4,906
Net Cash Per Share	-1.31	-2.25	-2.05	-1.18	-1.50	-3.93
Filing Date Shares Outstanding	1,467	1,467	1,467	1,467	1,467	1,247
Total Common Shares Outstanding	1,467	1,467	1,467	1,467	1,467	1,247
Working Capital	6,228	5,618	6,814	5,978	5,516	1,028
Book Value Per Share	8.27	8.12	8.39	7.78	7.88	5.89
Tangible Book Value	9,349	9,116	9,439	8,712	8,751	4,320
Tangible Book Value Per Share	6.37	6.21	6.43	5.94	5.96	3.46
Land	34.21	34	33.43	30.61	31.32	-
Buildings	1,793	1,791	1,480	1,450	1,445	-
Machinery	1,966	1,952	1,892	1,719	1,693	-
Construction In Progress	580.61	468.72	394.53	425.35	364.39	-

Source: S&P Capital IQ. Standard template. Financial Sources.